Steady price for Telus stock as share price declines 23% over past year

Traders Union
All News
Financial News
Telus slips 0.09% today to C$17.35

Highlights

TELUS expanded its #StandWithOwners initiative, injecting C$125,000 into Canadian small business support as part of ongoing ecosystem investment.
Despite a 23% share price drop over the past year, the company maintains a near 10% dividend yield and reports 11% revenue growth in TELUS Health.
Technicals indicate mild bullish short-term momentum but an overall bearish trend, with an expected price range of C$17.10–C$17.70 and higher probability of further weakness.

Strategic initiatives bolster ecosystem as shares face selling pressure

TELUS has launched its seventh annual #StandWithOwners contest, offering C$125,000 in funding, technology, and exposure to Canadian small business owners, which directly channels new capital into its business ecosystem and supports future client engagement. Since 2020, TELUS has allocated nearly $7 million to small business support, alongside $6 million in student bursaries and the formation of new partnerships with Google, Salesforce, Samsung, and Scotiabank to broaden the program’s impact. The company also reported a 23% decrease in share price over the past year, a current dividend yield near 10%, ongoing deleveraging efforts, and an 11% revenue growth in its TELUS Health division, all reflecting a strategic focus on financial stability and business diversification, though price action has remained under broader selling pressure.

Mixed momentum indicators temper optimism despite support holding

The current price of T sits above the SMA-20 at C$17.21 and SMA-50 at C$17.24, but below the SMA-200 at C$19.23, with the Ichimoku Kijun level positioned at C$17.13 as immediate support. Daily momentum indicators are mixed: the MACD and ADX on the daily timeframe remain neutral, while RSI at 54.85 and CCI at 73.87 show a mild bullish bias. Short-term oscillators such as Stoch RSI register overbought conditions at 100, contrasting with BBP data that confirms recent buyer dominance, suggesting caution amid mild intraday selling pressure and overall low volatility.

Limited breakout odds as consolidation dominates short-term outlook

Over the next five trading days, the anticipated price range for T is projected between C$17.10 and C$17.70, representing a zone of moderate volatility around current levels. The most likely scenario envisions continued consolidation within this band, with a low probability (less than 20%) of an upward breakout. Should upside momentum strengthen and break through C$17.70, T could test higher resistance levels; conversely, a consistent drop below the support at C$17.13 would risk further downside toward the lower end of the expected range.

Viktoras Karapetjanc, expert at Traders Union, notes that TELUS continues to expand its community-focused programs while maintaining strategic partnerships that strengthen its business model. He sees ongoing deleveraging and resiliency in key growth areas, such as TELUS Health, as constructive signals despite the share price lagging over the past year. Recent news flow and dividend stability could support renewed confidence among income investors. "TELUS is showing solid long-term foundations, and if volatility stays contained above support, upside potential remains in play."

Earlier, analysts noted that TELUS faced a period of sideways consolidation, with technical signals suggesting limited potential for sustained gains in the near term. The current combination of steady momentum, persistent overbought signals, and recent corporate initiatives reinforces the view that T is likely to remain rangebound, with any break beyond C$17.70 signaling a possible shift in market sentiment.

Source of Data: T Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.